What is AdreView?
AdreView (iobenguane I-123) belongs to a group of drugs called diagnostic radiopharmaceuticals. Iobenguane I-123 is a radioactive agent that allows images of specific organs in the body to be detected by a gamma camera.
AdreView is used to detect certain kinds of tumors.
AdreView is also used in people with congestive heart failure to assess the function of nerves that control the heart muscle. Iobenguane I-123 can detect nerve damage to help identify a patient's risk of death from heart failure.
You should not receive AdreView if you are allergic to iobenguane or iobenguane sulfate.
Tell your doctor if you have ever had any type of reaction to another contrast agent, or to potassium.
Before you are treated with AdreView, tell your doctor if you have kidney disease, a thyroid disorder, if you are dehydrated or unable to urinate, or if you are allergic to iodine.
Tell your doctor about all other medications you are using, especially antidepressants, cold medicines, blood pressure medications, or ADHD medications. You may need to stop using certain drugs for a short time before you receive AdreView.
Drink extra fluids before you receive AdreView, and for at least 48 hours afterward. Follow your doctor's instructions about the types and amount of liquids you should drink before and after your test. Iobenguane I 123 is radioactive and it can cause dangerous effects on your bladder if it is not properly eliminated from your body through urination. Do not allow yourself to become dehydrated during the first few days after receiving AdreView. Call your doctor if you have any vomiting or diarrhea during this time. Follow your doctor's instructions about the types and amount of fluids you should drink.
Before taking this medicine
You should not be treated with AdreView if you are allergic to iobenguane or iobenguane sulfate.
To make sure AdreView is safe for you, tell your doctor if you have ever had:
a thyroid disorder;
Parkinson's disease or other neurologic disorder;
high blood pressure;
if you are dehydrated or unable to urinate; or
if you are allergic to iodine.
Older adults may need kidney function tests before receiving AdreView. Your kidney function may also need to be watched closely after you have received this medication.
It is not known whether AdreView will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. There is a potential risk of fetal exposure to radiation while using iobenguane I-123.
It is not known whether iobenguane I-123 passes into breast milk or if it could harm a nursing baby. You should not breastfeed for at least 6 days after receiving AdreView. If you use a breast pump during this time, throw out any milk you collect. Do not feed it to your baby.
How is AdreView given?
AdreView is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. It is usually given about 24 hours before your radiologic test.
At least 1 hour before you are treated with AdreView, you may be given a liquid drink that contains medicine to protect your thyroid from harmful radioactive effects of iobenguane I-123.
Drink extra fluids before you receive AdreView, and for at least 48 hours afterward. Follow your doctor's instructions about the types and amount of liquids you should drink before and after your test. Iobenguane I-123 is radioactive and it can cause dangerous effects on your bladder if it is not properly eliminated from your body through urination.
Expect to urinate often during the first 48 hours after your test. You will know you are getting enough extra fluid if you are urinating more than usual during this time. Urinating often will help rid your body of the radioactive iodine.
What happens if I miss a dose?
Since AdreView is given only once before your radiologic test, you will not be on a dosing schedule.
Call your doctor if for some reason you will not be able to complete your radiologic test within 24 hours after you receive your injection.
What happens if I overdose?
Since this medication is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
What should I avoid while receiving AdreView?
Do not allow yourself to become dehydrated during the first few days after receiving AdreView. Call your doctor if you have any vomiting or diarrhea during this time. Follow your doctor's instructions about the types and amount of fluids you should drink.
AdreView side effects
Get emergency medical help if you have signs of an allergic reactionto AdreView: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Common AdreView side effects may include:
flushing (warmth, redness, or tingly feeling);
bleeding around your IV needle.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect AdreView?
Some medicines can interfere with the quality of images produced by AdreView. Tell your doctor about all your current medicines and any you recently stopped using, especially:
an antidepressant such as amitriptyline, bupropion, citalopram, desipramine, fluoxetine, imipramine, paroxetine, sertraline, Wellbutrin, Zoloft, Prozac, Celexa, and others;
blood pressure medication; or
cough, cold, or allergy medicine that contains a decongestant (phenylephrine or pseudoephedrine).
This list is not complete. Other drugs may interact with iobenguane I-123, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
More about AdreView (iobenguane I 123)
- Side Effects
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: diagnostic radiopharmaceuticals
- FDA Approval History
Related treatment guides
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use AdreView only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2022 Cerner Multum, Inc. Version: 5.01.